Abstract
Introduction: Aromatase inhibitors (AIs) are the gold standard adjuvant treatment for post-menopausal women with oestrogen-receptor positive breast cancer (BC) but accelerate bone loss and increase fracture risk. The 2008 UK consensus statement recommends measurement of baseline bone mineral density with Dual Energy X-ray Absorptiometry (DEXA) within 6 months of commencing an AI with a follow up scan at 24 months if medium/high risk or clinically indicated. We present a re-audit of our unit's compliance with national bone health standards following the introduction of a separate dedicated service run by an Osteoporosis nurse specialist and an Elderly Care physician in November 2013.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
